One study demonstrated CD30 protein expression by immunohistochemistry (IHC) in around 5% of triple negative breast cancer cases,[1] and another recent study showed that CD30 protein expression by immunohistochemistry was seen with a higher sensitivity in breast cancer with a high CD30 gene RNA level.[14] Such information could potentially be of great clinical benefit, especially given that anti-CD30 targeted therapy has been shown to be effective against CD30-positive neoplasms.[15]. Here, TNFRSF8 is linked to triple-negative breast carcinoma.